NuVasive (NUVA +4.5%) pops on a Baird upgrade to outperfrom. Baird cites its proprietary survey...
NuVasive (NUVA +4.5%) pops on a Baird upgrade to outperfrom. Baird cites its proprietary survey of spine/neurosurgeons suggesting spine market dynamics are somewhat flat, but the industry's conversion to lateral lumbar fusion creates an opportunity for NuVasive to gain market share.
From other sites
at CNBC.com (Oct 4, 2012)
at CNBC.com (Oct 3, 2012)
at CNBC.com (Jun 28, 2012)
at CNBC.com (Jun 23, 2010)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs